J. Zanchetta

发表

Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance

H. Plotkin, E. Rold'an, J. Zanchetta, 1996, Calcified Tissue International.

Bone mass in children: normative values for the 2-20-year-old population.

H. Plotkin, J. Zanchetta, J. Zanchetta, 1995, Bone.

Bone microarchitecture in Rett syndrome and treatment with teriparatide: a case report

M. Zanchetta, J. Zanchetta, M. F. Scioscia, 2016, Osteoporosis International.

Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study

C. Bogado, M. Zanchetta, J. Zanchetta, 2017, Osteoporosis International.

Calcium Bioavailability and Parathyroid Hormone Acute Changes after Oral Intake of Dairy and Nondairy Products in Healthy Volunteers

J. Zanchetta, S. Seccia, M. Roberts, 1999, Osteoporosis International.

The vacuum cleft sign: an uncommon radiological sign

F. P. Pérez Manghi, J. Zanchetta, M. Sarli, 2005, Osteoporosis International.

Effects of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] on Cortical Bone in Postmenopausal Women With Osteoporosis

J. Zanchetta, M. Sato, G. Gaich, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial

A. Harris, J. Bilezikian, D. Hans, 2017, Osteoporosis International.

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures

S. Silverman, B. Mitlak, R. Burge, 2012, Osteoporosis International.

The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS)

S. Cummings, L. Palermo, J. Zanchetta, 2009, Osteoporosis International.

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

E. Shane, J. Zanchetta, M. Maricic, 2009, Osteoporosis International.

Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis

J. Zanchetta, D. Cox, S. Dowsett, 2012, Osteoporosis International.

Lumbar spine bone density in argentine children

H. Plotkin, J. Zanchetta, J. Zanchetta, 1996, Calcified Tissue International.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

S. Boonen, P. Delmas, C. Roux, 2012, Osteoporosis International.

H. Plotkin, J. Zanchetta, R. Capozza, 1998, Bone.

OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density

A. Díez-Pérez, A. Grauer, A. Chines, 2015 .